Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer
Fernando J. de Miguel(Yale Cancer Center), Katerina Politi(Yale Cancer Center)
Cited by 103
Related Papers
ASCL1 Drives Tolerance to Osimertinib in <i>EGFR</i> Mutant Lung Cancer in Permissive Cellular Contexts
|Cancer Research|2024|24
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer
|The Journal of Experimental Medicine|2024|19